MedDRA preferred term · a problem with the packaging

Product packaging issue: adverse event reports recording this term

9,159 reports to FDA record it, 2009–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

9,159
reports recording the term: 0% of all reports; 939
reports, 12 months to June 2026: 560 in the 12 months before; 19.7%
marked serious by the reporter: 57.4% across all reports; 0.6%
record death among outcomes, as reported: 9.1% across all reports

"Product packaging issue" (in plain words, a problem with the packaging) is a MedDRA preferred term recorded in 9,159 adverse event reports received by FDA, 0% of the database, from September 2009 to June 2026. The term is chosen by whoever codes the report to match what the reporter described.

939 reports recorded it in the 12 months to June 2026, up 68% from 560 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 19.7% are marked serious, 0.6% include death among the outcomes and 5.2% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Estradiol, Imodium Multi-Symptom Relief and Stelara. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Estradiol	Estrogen	327	2.1%
Imodium Multi-Symptom Relief	—	317	5.9%
Stelara	Interleukin-12 antagonist	226	0.3%
TYLENOL Extra Strength	—	206	2.6%
Imodium A-D	Opioid agonist	197	5.7%
Zyrtec	Histamine-1 receptor antagonist	138	0.7%
Imodium	Opioid agonist	113	1.9%
Xarelto	Factor Xa inhibitor	94	0.1%
Simponi	Tumor necrosis factor blocker	90	0.1%
Tremfya	Interleukin-23 antagonist	86	0.3%
Cosentyx	Interleukin-17A antagonist	83	0.1%
Oxytrol for Women	Cholinergic muscarinic antagonist	83	1.3%
Tylenol 8 HR Arthritis Pain	—	82	1.7%
Prezista	Protease inhibitor	79	1.3%
Restasis	Calcineurin inhibitor immunosuppressant	79	0.4%
Womens Rogaine Unscented	Arteriolar vasodilator	79	0.7%
Duragesic	—	72	0.2%
Fentanyl	Opioid agonist	63	0.1%
Mens Rogaine Extra Strength	—	63	0.5%
Humira	—	62	0%
Aimovig	—	59	0.1%
Paxlovid	—	57	0.1%
Ozempic	GLP-1 receptor agonist	56	0.1%
Xiidra	—	55	0.4%
Eliquis	Factor Xa inhibitor	53	0%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Opioid agonist	427	0%	0%
Estrogen	425	0.3%	0%
Interleukin-12 antagonist	226	0.2%	0.2%
Histamine-1 receptor antagonist	225	0.2%	0%
Nonsteroidal anti-inflammatory drug	207	0%	0%
Tumor necrosis factor blocker	179	0%	0%
Corticosteroid	176	0%	0%
Factor Xa inhibitor	147	0%	0%
Kinase inhibitor	116	0%	0%
Prostaglandin analog	104	0.2%	0.1%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.4%40

2 to 111.5%140

12 to 170.6%59

18 to 446.2%567

45 to 6412.9%1,184

65 to 749.7%886

75 and over11.5%1,051

Age not given57.1%5,232

Patient sex

Female56%5,132

Male23.5%2,148

Not given20.5%1,879

Grey bar: all 20,646,523 reports in the database. 89.1% of these reports give the United States as the country.

Questions about "Product packaging issue"

What does "Product packaging issue" mean in an adverse event report?

In plain language: a problem with the packaging. It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record product packaging issue?

9,159 reports through June 2026 (0% of all reports), 939 of them in the latest 12 months.

Which drugs appear most often in these reports?

Estradiol (327), Imodium Multi-Symptom Relief (317), Stelara (226), TYLENOL Extra Strength (206) and Imodium A-D (197). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.